



SEQ ID NO:1

MTQDCSFQHS PISSDFAVKI RELSDYLLQD YPVTVASNLQ
DEELCGGLWR LVLAQRWMER LKTVAGSKMQ HFVTKCAFQP
PPSCLRFVQT NISRLLOETS EQLVALKPWI TRQNFSRCLE
LQCQPDSSSTL PPPWSPRPLE ATAPTA

FIG._1

SEQ ID NO:2

MEGICRNRVT NNVKDVTCLV ANLPKDYMITE LKYVPGMDVL
PSHCWISEMV VQLSDSLTDL LDKFSNISEG LSNYSIIDKL
VNIVDDLVEC VKENSSKDLK KSFKSPEPRL FTPEEFFRIF
NRSIDAFKDF VVASETSDCV VSSTLSPEKD SRVSVTKPFM
LPPVA

FIG._2

SEQ ID NO:3

PVPPGEDSKD VAAPHRQPLT SSERIDKQIR YILDGISALR
KETCNKSNMC ESSKEALAEN NLNLPKMAEK DGCFOSGFNE
ETCLVKIITG LLEFEVYLEY LQNRFESEEE QARAVQMSTK
VLIQFLQKKA KNLDAITTPD PTTNASLLTK LQAQNQWLQD
MTTHLILRSF KEFLQSSLRA LRQM

FIG._3

SEQ ID NO:4

MHKCDITLQE IIKTLNSLTE QKTLCTELTV TDIFAASKNT
TEKETFCRAA TVLRQFYSHH EKDTRCLGAT AQQFHRHKQL
IRFLKRLDRN LWGLAGLNSC PVKEANQSTL ENFLERLKTI
MREKYSKCSS

FIG._4

SEQ ID NO:5

MAPMTQTTSL KTSWVNCSNM IDEIITHLKQ PPLPLLDENN
LNGEDQDILM ENNLRRPNLE AFNRAVKSLQ NASAIESILK
NLLPCLPLAT AAPTRHPIHI KDGDWNEFRR KLTFYKLTLE
NAQAQQTTLA LAIF

FIG._5



2 / 14




FIG._6A




FIG._6B





FIG._7A-1




FIG._7A

4 / 14





FIG. 7A-2

5 / 14






FIG..7B-1




FIG..7B

7 / 14




FIG. 7B-2






FIG. 7B-3



CHMC.3
"unprimed"



CHMC.3
"primed"

FIG..7C-1

FIG..7C-1 | FIG..7C-2 | FIG..7C-3

FIG..7C

10 / 14





FIG. 7C-2

11 / 14






FIG._8A




FIG._8B




FIG._8C




FIG._8D

**Stimulation Profile of CHMC's
(Performed in Triplicate)**

IL-5 ELISA On SNT, 6 Hour Post Chase




FIG._8E

**Stimulation Profile of CHMC's
(Performed in Triplicate)**

IL-13 ELISA On SNT, 6 Hour Post Chase




FIG._8F

**Stimulation Profile of CHMC's
(Performed in Triplicate)**

TNF-alpha ELISA On SNT, 6 Hour Post Chase




FIG._8G

CD Profile Summary For CHMC's**A****CD15, CD11b, and CD13:**

CD15 pos:	3%
CD11b pos:	0%
CD13 pos:	35%
CD15/13 pos:	3%
CD11b/13 pos:	2%
CD11b/15pos:	1%

CD15/13 neg:	55%
CD11b/13 neg:	59%
CD11b/15 neg:	92%

C**CD15, CD11b, and CD14:**

CD15 pos:	4%
CD11b pos:	0%
CD14 pos:	39%
CD15/14 pos:	4%
CD11b/14 pos:	2%
CD11b/15pos:	0%

CD15/14 neg:	53%
CD11b/14 neg:	56%
CD11b/15 neg:	91%

B**CD34, CD11b, and CD13:**

CD34 pos:	0%
CD11b pos:	0%
CD13 pos:	32%
CD34/13 pos:	1%
CD11b/13 pos:	1%
CD11b/15pos:	0%

CD34/13 neg:	66%
CD11b/13 neg:	66%
CD11b/34 neg:	97%

D**CD34, CD11b, and CD14:**

CD34 pos:	0%
CD11b pos:	0%
CD14 pos:	37%
CD34/14 pos:	0%
CD11b/14 pos:	2%
CD11b/34pos:	0%

CD34/14 neg:	58%
CD11b/14 neg:	58%
CD11b/34neg:	96%

FIG._9